Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + EOX in Resectable Gastric Cancer
NCT01351038Phase 2Terminated
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in gastric adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Primary endpoints: Efficacy and Safety. Status: terminated.
02
Drugs
panitumumab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT01351038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01351038.